Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

TB-500 Wound Repair Research Models: UK 2026

TB-500 accelerates healing by modulating actin dynamics, promoting cell migration, stimulating angiogenesis, and reducing inflammation.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

TB-500 Wound Repair Research Models: UK 2026

Important regulatory notice. TB-500 is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference compound and appears on the WADA Prohibited List in sport. This page is a literature-context overview of the published research record on TB-500 in wound-repair models. It is not personal-use guidance.

Quick research summary. TB-500 is a synthetic peptide containing an active fragment from thymosin beta-4. The published wound-repair literature is dominated by in-vitro and rodent-model work and reports observations on cellular migration, actin biology and angiogenesis-related signalling. Large human clinical-trial data is not available, so consumer ‘speeds healing’ framings sit outside the public regulatory evidence base.

What the cell-biology literature reports

Thymosin beta-4 has been studied for several decades in the context of cellular migration, actin polymerisation and angiogenesis-related gene expression. The synthetic TB-500 fragment is described as containing an active sequence from this protein. Cell-culture wound-closure assays describe protocol-defined cellular-migration endpoints over hours to days. These are biochemistry observations in cell-culture systems and do not translate one-for-one to human outcomes.

What the rodent-model literature reports

Rodent wound-repair studies report protocol-defined endpoints across one to four weeks, with the dose, route and outcome measure varying by study. Independent reviewers note that rodent-model findings have not been corroborated in published large human clinical trials.

UK regulatory and sport-testing position

TB-500 has not received UK marketing authorisation. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. TB-500 is also a WADA-banned substance and WADA-accredited laboratories run targeted assays for it.

For laboratory researchers

TB-500 is widely used as a research reference compound in cell-biology and small-animal model work. Quality requirements for any research-grade reference sample are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling. Peptides Lab UK supplies on that basis.

Frequently Asked Questions

Does TB-500 speed up healing in humans?

Published large human clinical-trial data is not available. The evidence base is dominated by in-vitro and rodent-model work and is not a basis for personal-use efficacy predictions.

Is TB-500 licensed in the UK?

No. TB-500 has not received MHRA, EMA or FDA marketing authorisation.

Is TB-500 banned in sport?

Yes. TB-500 appears on the WADA Prohibited List.

Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. TB-500 is also banned in sport under the WADA Prohibited List.

You May Also Like

Connected topics

Follow this recovery question